Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-702X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy ; volume:256 ; number:8 ; day:19 ; month:5 ; year:2018 ; pages:1411-1418 ; date:8.2018
Graefe's archive for clinical and experimental ophthalmology ; 256, Heft 8 (19.5.2018), 1411-1418, 8.2018
- Urheber
-
Mikhail, Michael
- Beteiligte Personen und Organisationen
-
Stewart, Stephen
Seow, Felicia
Hogg, Ruth
Lois, Noemi
SpringerLink (Online service)
- DOI
-
10.1007/s00417-018-4009-6
- URN
-
urn:nbn:de:101:1-2018091920321268893317
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mikhail, Michael
- Stewart, Stephen
- Seow, Felicia
- Hogg, Ruth
- Lois, Noemi
- SpringerLink (Online service)
Ähnliche Objekte (12)
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries